Literature DB >> 17763333

Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.

Robert K Ernst1, Samuel M Moskowitz, Julia C Emerson, Gretchen M Kraig, Kristin N Adams, Megan D Harvey, Bonnie Ramsey, David P Speert, Jane L Burns, Samuel I Miller.   

Abstract

Three structural features of lipid A (addition of palmitate [C16 fatty acid], addition of aminoarabinose [positively charged amino sugar residue], and retention of 3-hydroxydecanoate [3-OH C10 fatty acid]) were determined for Pseudomonas aeruginosa isolates from patients with cystic fibrosis (CF; n=86), from the environment (n=13), and from patients with other conditions (n=14). Among P. aeruginosa CF isolates, 100% had lipid A with palmitate, 24.6% with aminoarabinose, and 33.3% retained 3-hydroxydecanoate. None of the isolates from the environment or from patients with other conditions displayed these modifications. These results indicate that unique lipid A modifications occur in clinical P. aeruginosa CF isolates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763333      PMCID: PMC2723782          DOI: 10.1086/521367

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections.

Authors:  Dao Nguyen; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-22       Impact factor: 11.205

2.  Dissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residues.

Authors:  Jeroen Geurtsen; Liana Steeghs; Jan Ten Hove; Peter van der Ley; Jan Tommassen
Journal:  J Biol Chem       Date:  2004-12-20       Impact factor: 5.157

3.  Detergent-accelerated hydrolysis of bacterial endotoxins and determination of the anomeric configuration of the glycosyl phosphate present in the "isolated lipid A" fragment of the Bordetella pertussis endotoxin.

Authors:  M Caroff; A Tacken; L Szabó
Journal:  Carbohydr Res       Date:  1988-04-15       Impact factor: 2.104

4.  Human Toll-like receptor 4 recognizes host-specific LPS modifications.

Authors:  Adeline M Hajjar; Robert K Ernst; Jeff H Tsai; Christopher B Wilson; Samuel I Miller
Journal:  Nat Immunol       Date:  2002-03-25       Impact factor: 25.606

5.  Bacterial biofilms and catheters in experimental urinary tract infection.

Authors:  T Goto; Y Nakame; M Nishida; Y Ohi
Journal:  Int J Antimicrob Agents       Date:  1999-05       Impact factor: 5.283

6.  Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.

Authors:  M Rosenfeld; R L Gibson; S McNamara; J Emerson; J L Burns; R Castile; P Hiatt; K McCoy; C B Wilson; A Inglis; A Smith; T R Martin; B W Ramsey
Journal:  Pediatr Pulmonol       Date:  2001-11

7.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

Review 8.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

9.  PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A.

Authors:  Samuel M Moskowitz; Robert K Ernst; Samuel I Miller
Journal:  J Bacteriol       Date:  2004-01       Impact factor: 3.490

10.  Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis.

Authors:  I Pujana; L Gallego; G Martín; F López; J Canduela; R Cisterna
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

View more
  48 in total

1.  Vanadate and triclosan synergistically induce alginate production by Pseudomonas aeruginosa strain PAO1.

Authors:  F Heath Damron; Michael R Davis; T Ryan Withers; Robert K Ernst; Joanna B Goldberg; Guangli Yu; Hongwei D Yu
Journal:  Mol Microbiol       Date:  2011-06-16       Impact factor: 3.501

Review 2.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 3.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

4.  A Screen for Antibiotic Resistance Determinants Reveals a Fitness Cost of the Flagellum in Pseudomonas aeruginosa.

Authors:  E A Rundell; N Commodore; A L Goodman; B I Kazmierczak
Journal:  J Bacteriol       Date:  2020-02-25       Impact factor: 3.490

Review 5.  Innate immunity in the respiratory epithelium.

Authors:  Dane Parker; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2011-02-17       Impact factor: 6.914

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

7.  A divergent Pseudomonas aeruginosa palmitoyltransferase essential for cystic fibrosis-specific lipid A.

Authors:  Iyarit Thaipisuttikul; Lauren E Hittle; Ramesh Chandra; Daniel Zangari; Charneal L Dixon; Teresa A Garrett; David A Rasko; Nandini Dasgupta; Samuel M Moskowitz; Lars Malmström; David R Goodlett; Samuel I Miller; Russell E Bishop; Robert K Ernst
Journal:  Mol Microbiol       Date:  2013-11-27       Impact factor: 3.501

8.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

Review 9.  Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.

Authors:  Elio Rossi; Ruggero La Rosa; Jennifer A Bartell; Rasmus L Marvig; Janus A J Haagensen; Lea M Sommer; Søren Molin; Helle Krogh Johansen
Journal:  Nat Rev Microbiol       Date:  2020-11-19       Impact factor: 60.633

10.  An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.

Authors:  Elena K Schneider; Mohammad A K Azad; Mei-Ling Han; Qi Tony Zhou; Jiping Wang; Johnny X Huang; Matthew A Cooper; Yohei Doi; Mark A Baker; Phillip J Bergen; Mark T Muller; Jian Li; Tony Velkov
Journal:  ACS Infect Dis       Date:  2016-05-17       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.